The Muscular Dystrophy Association (MDA) and Lowe’s stores are joining efforts to launch the MDA’s Shamrock program, the largest St. Patrick’s Day philanthropic event dedicated to help patients who live with the disabling muscle disease Duchenne muscular dystrophy. The FORTUNE 100 home improvement…
News
A recent study was published in The Lancet Neurology journal showing that a specific cardiac drug is able to induce cardiac function improvement in boys with muscular dystrophy and cardiomyopathy. The study is entitled “Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a…
BioBlast Pharma Ltd. presented the preliminary results from its HOPEMD Phase 2/3 study investigating Cabaletta (trehalose) in patients with Occulopharyngeal Muscular Dystrophy (OPMD), a progressive, incapacitating genetic disease. Cabaletta is a chemical chaperone that has been shown to reduce pathological aggregation of proteins within cells in several diseases…
Dr. Thomas Gionis The use of stem cell therapy for a wide range of diseases continues to gain momentum across the United States, with more and more patients and their families seeking information about the benefits and potential risks of the treatment. In answer to this, clinics such as…
The Muscular Dystrophy Association (MDA) has released a report on the latest findings and developments on treatments for Duchenne muscular dystrophy that combat fibrosis and heart conditions associated with the disease. The Drug Development for DMD: February 2015…
A new study entitled, “Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers” was recently completed through a joint collaboration between researchers from the CNRS, UVSQ and INSERM at both the Laboratoire END-ICAP and the University of Bern. They discovered that through RNA “surgery,” synthetic oligonucleotides may…
News
tcDNA-antisense Oligonucleotides Offer Promising, New Therapeutics for Duchenne Muscular Dystrophy
A new study entitled “Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers” shows a new class of antisense oligonucleotides – tcDNA- antisense oligonucleotides – are highly efficient at rescuing dystrophin levels and improving symptoms in a mouse model of Duchenne muscular dystrophy.
The Muscular Dystrophy Association recently announced the start of the 13th annual “Appetite for a Cure” campaign to raise critically-needed funds and mobilize awareness to help the MDA improve the lives of both children and adults who live with muscular dystrophy. From February 2 through March 22, more than 130 Sailormen/Popeye’s restaurants will participate…
Nominations for individuals who wish to serve as non-federal public members on the Muscular Dystrophy Coordinating Committee (MDCC) are currently open and being accepted by the office of the Secretary of the Department of Health and Human Services (HHS) until February 27. The MDCC is a federal advisory commission that was created…
The nonprofit organization, Parent Project Muscular Dystrophy (PPMD), has announced it will award a $50,000 exploratory grant to a research team from UCLA‘s David Geffen School of Medicine and College of Letters and Science, led by Dr. M. Carrie Miceli. The funding will support the study of exon skipping boosters for the treatment of DMD,…
Recent Posts
- I won’t apologize for having 3 children with Duchenne MD
- FDA clears trial testing Mesoblast cell therapy in kids with DMD
- Seeing ‘Les Misérables’ reminds me of the arc of my own life with DMD
- ‘Be Their Muscle’ MDA campaign marks 10 years of workouts, fundraising
- How to combat social isolation while growing older with muscular dystrophy